🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Terazosin

    Hospital Authority, Hong Kong

    Stent Related Symptoms

    phase 3 small molecule active

    1 trial

  2. Testosterone Gel 1%, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Bomba de gel transparente, donde la sustancia activa (testosterona) fue sustituida por agua purificada.

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    phase 3 small molecule active

    1 trial

  3. Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  4. Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  5. Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic Rhinosinusitis with Nasal Polyposis

    phase 3 small molecule active

    1 trial

  6. Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Severe Asthma

    phase 3 small molecule active

    1 trial

  7. Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo

    AstraZeneca AB

    Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

    phase 3 small molecule active

    1 trial

  8. The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose.

    Minoryx Therapeutics S.L.

    Cerebral adrenoleukodystrophy (cALD)

    phase 3 small molecule active

    1 trial

  9. The methylprednisolone sodium succinate

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  10. The placebo product is manufactured to visually match the corresponding FDY-5301 injection drug product. It is formulated to match a standard saline solution comprised of Sodium Chloride and Water for Injection.

    Lacuna Pharma Pty Ltd

    Anterior ST-Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  11. Thoracoscopic Bullectomy Surgery

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stability During Surgical Operation

    phase 3 other active

    1 trial

  12. Tiaoshen Anti-cancer Granules

    The First People's Hospital of Lianyungang

    Ovarian Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  13. Ticagrelor and Aspirin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 3 small molecule completed

    1 trial

  14. Tinidazole oral microneedle patch

    The First People's Hospital of Lianyungang

    Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

    phase 3 other active

    1 trial

  15. Tiratricol

    Ultragenyx UK Limited

    Monocarboxylate Transporter 8 Deficiency

    phase 3 small molecule completed

    1 trial

  16. Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)

    Rare Thyroid Therapeutics International AB

    Monocarboxylate Transporter 8 (MCT8) deficiency

    phase 3 small molecule active

    1 trial

  17. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colonic Neoplasms

    phase 3 small molecule active

    1 trial

  18. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Carcinoma

    phase 3 small molecule active

    1 trial

  19. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  20. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  21. Tislelizumab（neoadjuvant）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinomas

    phase 3 small molecule active

    1 trial

  22. Tissue Plasminogen Activator (Alteplase)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 3 small molecule completed

    1 trial

  23. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  24. Topical application of Periplaneta americana-derived Meilian Fuxin Solution

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-induced Dermatitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources